Friday 6 November 2026
Export IQV’s income statement to Excel — free account
IQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024.
- Revenue
- +8.00%
- EPS
- +10.2%
- Free cash flow
- −21.3%
- Total debt
- +7.42%
Quarter to September 2026, against a year earlier
269.78
4.90
+1.85%
Follow IQV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
28.43 | 20.95 | 23.77 | 32.29 |
P/S ratio |
2.38 | 1.73 | 1.89 | 2.56 | |
P/FCF ratio |
18.23 | 13.11 | 14.21 | 21.30 | |
P/Operating CF |
52.72 | 46.47 | 57.52 | 53.67 | |
P/B ratio |
5.84 | 4.52 | 5.09 | 6.52 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.21 | 2.55 | 2.71 | 3.35 | |
EV/EBITDA |
15.63 | 12.52 | 13.51 | 16.74 | |
EV/Operating CF |
19.72 | 15.70 | 16.32 | 21.17 | |
EV/FCF |
24.61 | 19.37 | 20.37 | 27.86 | |
Quick Ratio |
0.67 | 0.66 | 0.62 | 0.74 | |
Current Ratio |
0.75 | 0.75 | 0.71 | 0.83 | |
Net Debt/EBITDA |
14.30 | 16.99 | 17.31 | 15.19 | |
Debt/Assets |
52.51% | 53.35% | 53.54% | 52.72% | |
Debt/Equity |
2.37 | 2.49 | 2.54 | 2.37 | |
Asset Turnover |
0.57 | 0.58 | 0.58 | 0.58 | |
Operating CF/Net income |
1.43 | 2.26 | 2.18 | 2.36 | |
Capex/Depreciation |
(0.54) | (0.43) | (0.66) | (0.48) | |
Interest Coverage |
3.25 | 2.68 | 2.57 | 2.82 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
10.72% | 12.09% | 13.14% | 12.85% | |
Intangible Assets out of Total Assets |
0.72 | 0.72 | 0.71 | 0.71 | |
Share Based Compensation of Revenue |
1.37% | 1.57% | 2.17% | 1.87% | |
Graham Net Nets |
(0.44) | (0.60) | (0.54) | (0.39) | |
Graham Number |
82.96 | 83.10 | 83.30 | 87.89 | |
Earnings Yield |
3.52% | 4.77% | 4.21% | 3.10% | |
Free Cash Flow Yield |
5.49% | 7.63% | 7.04% | 4.70% | |
Revenue per Share |
25.39 | 24.65 | 26.30 | 26.89 | |
Operating CF per Share |
4.28 | 3.67 | 3.36 | 5.01 | |
Capex per Share |
(1.01) | (0.75) | (1.19) | (0.96) | |
Free Cash Flow per Share |
3.26 | 2.92 | 2.17 | 4.05 | |
Cash per Share |
12.45 | 12.49 | 12.52 | 14.71 | |
Shareholders Equity per Share |
38.57 | 37.70 | 37.94 | 41.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
38.57 | 37.70 | 37.94 | 41.23 | |
Free Cash Flow |
561.00 | 491.00 | 360.00 | 667.00 | |
Working Capital |
(2,089.00) | (2,109.00) | (2,589.00) | (1,326.00) | |
Capital Expenditures |
(174.00) | (127.00) | (198.00) | (158.00) | |
Net Current Asset Value |
(17,065.00) | (17,106.00) | (17,354.00) | (17,232.00) | |
EV/EBIT |
23.98 | 19.30 | 20.91 | 26.10 | |
Capex to Sales |
0.04 | 0.03 | 0.05 | 0.04 | |
Price to Operating Income |
17.76 | 13.05 | 14.59 | 19.95 | |
| Other line items | |||||
Average Receivables |
3,333.50 | 3,343.00 | 3,396.50 | 3,323.00 | |
Average Payables |
3,717.50 | 3,599.00 | 3,503.50 | 3,613.00 | |
Average Assets |
28,421.50 | 28,498.50 | 29,256.50 | 29,600.50 | |
Average Common Equity |
6,348.50 | 6,167.00 | 6,043.50 | 6,539.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026